Biotechnology companies develop treatments for some of medicine's most challenging diseases, from cancer and autoimmune disorders to rare genetic conditions. Regeneron and Amgen are established biopharmaceutical leaders with deep pipelines, while CRISPR Therapeutics and Moderna represent the cutting edge of gene editing and mRNA technology. Biotech stocks carry binary risk around clinical trial results but offer the potential for outsized returns when therapies succeed.
1
4.6
Regeneron Pharmaceuticals
REGN
$803.17
+2.49%
P/E: 32.8
Regeneron is a top-tier biotech stock powered by its industry-leading antibody discovery platform and the explosive growth of Dupixent across multiple inflammatory indications, demonstrating the kind of science-driven innovation and commercial execution that biotech investors seek.
2
4.5
Amgen
AMGN
$369.19
+0.82%
P/E: 22.0
Amgen is a cornerstone biotech stock representing one of the industry's most successful companies, with a deep pipeline of biologic therapies, a proven track record of bringing innovative medicines to market, and the scale to invest billions annually in research and development across multiple thera
3
4.5
CRISPR Therapeutics
CRSP
$53.07
+8.46%
P/E: 2.9
CRISPR Therapeutics is at the frontier of biotechnology with its gene-editing platform, having achieved the historic milestone of the first approved CRISPR-based therapy and pursuing a deep pipeline of next-generation treatments.
4
4.4
Gilead Sciences
GILD
$154.98
+2.09%
P/E: 17.8
Gilead Sciences is a biotech pioneer in antiviral therapies, with groundbreaking treatments for HIV and hepatitis C, and is expanding its oncology pipeline through acquisitions and internal development of cell therapies and antibody-drug conjugates.
5
3.3
Moderna
MRNA
$42.23
+5.29%
Moderna exemplifies the innovative potential of biotech investing, having built an entire therapeutic platform around mRNA technology that extends far beyond its landmark COVID-19 vaccine into oncology, rare diseases, and personalized medicine, offering investors exposure to what could become a foun
Latest from Otrai
Every trader has a strategy that looks great in their head. Backtesting is how you find out whether it actually works. Here is how to test strategies properly, what metrics matter, and why most backtest results are too good to be true.
A risk-reward ratio compares how much you stand to lose on a trade to how much you stand to gain. It is arguably the most important number in your trading plan, because it determines whether your strategy can survive a normal losing streak.
Every month, a handful of economic data releases move the forex market more in five minutes than most sessions move in five days. Non-Farm Payrolls, CPI prints, and central bank rate decisions create violent spikes, whipsaws, and trend shifts that can make or break a trading account.
A CFD is a contract between you and your broker to exchange the difference in an asset's price from when you open the trade to when you close it. You never own the underlying asset. That single distinction shapes everything about how CFDs work, what they cost, and why regulators treat them differently from traditional investing.